AustralianSuper Pty Ltd Buys 5,106 Shares of United Therapeutics Corporation $UTHR

AustralianSuper Pty Ltd grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 1.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 287,845 shares of the biotechnology company’s stock after buying an additional 5,106 shares during the quarter. AustralianSuper Pty Ltd owned approximately 0.64% of United Therapeutics worth $82,712,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of UTHR. Nuveen LLC purchased a new stake in United Therapeutics in the 1st quarter worth approximately $83,533,000. Amundi lifted its holdings in United Therapeutics by 198.8% in the 1st quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after buying an additional 232,988 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in United Therapeutics in the 2nd quarter worth approximately $55,746,000. Acadian Asset Management LLC lifted its holdings in United Therapeutics by 1,657.8% in the 1st quarter. Acadian Asset Management LLC now owns 179,205 shares of the biotechnology company’s stock worth $55,217,000 after buying an additional 169,010 shares during the period. Finally, Invesco Ltd. lifted its holdings in United Therapeutics by 46.1% in the 1st quarter. Invesco Ltd. now owns 465,115 shares of the biotechnology company’s stock worth $143,381,000 after buying an additional 146,664 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on UTHR shares. JPMorgan Chase & Co. dropped their price objective on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a report on Tuesday, July 8th. Cantor Fitzgerald increased their price objective on United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Jefferies Financial Group raised their target price on United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Weiss Ratings restated a “hold (c+)” rating on shares of United Therapeutics in a research note on Friday. Finally, Morgan Stanley raised their target price on United Therapeutics from $328.00 to $435.00 and gave the company an “equal weight” rating in a research note on Friday, October 10th. Nine research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $461.62.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $11,356,133.75. This trade represents a 23.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The disclosure for this sale can be found here. Insiders have sold 322,935 shares of company stock valued at $133,361,282 in the last quarter. 10.30% of the stock is owned by company insiders.

United Therapeutics Trading Down 1.8%

Shares of NASDAQ:UTHR opened at $418.58 on Monday. The stock has a fifty day simple moving average of $397.39 and a two-hundred day simple moving average of $332.98. The stock has a market capitalization of $18.88 billion, a price-to-earnings ratio of 16.34, a PEG ratio of 4.56 and a beta of 0.66. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $459.48.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The firm’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.85 EPS. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.